Get the Stockscreener App
20.25
0.20%
-0.04
Pelthos Therapeutics Inc. stock is traded at $20.25, with a volume of 44,471.
It is down -0.20% in the last 24 hours and down -0.34% over the past month.
See More
Previous Close:
$20.29
Open:
$20.14
24h Volume:
44,471
Relative Volume:
0.96
Market Cap:
$77.53M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-1.22%
1M Performance:
-0.34%
6M Performance:
-11.96%
1Y Performance:
-26.71%
1-Day Range:
$0.00
$0.00
1-Week Range:
$19.52
$21.16
52-Week Range:
$18.19
$37.50
Pelthos Therapeutics Inc. Stock (PTHS) Company Profile
Name
Pelthos Therapeutics Inc.
Sector
Industry
Phone
-
Address
-
Compare PTHS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTHS
Pelthos Therapeutics Inc.
|
20.25 | 77.53M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.38 | 128.85B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.63 | 94.87B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.99 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.57 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.40 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pelthos Therapeutics Inc. Stock (PTHS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-27-26 | Initiated | Piper Sandler | Overweight |
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-03-25 | Initiated | Lake Street | Buy |
| Nov-25-25 | Initiated | Roth Capital | Buy |
| Sep-02-25 | Initiated | Oppenheimer | Outperform |
View All
Pelthos Therapeutics Inc. Stock (PTHS) Latest News
Pelthos Therapeutics (PTHS) Stock Fair Value Falls After Analysts Cut Zelsuvmi Launch Estimates - Yahoo Finance
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Rating Lowered by Zacks Research - MarketBeat
Pelthos Therapeutics director Matthew Pauls sells $16,506 in shares By Investing.com - Investing.com Australia
Pelthos Therapeutics director sells $11,560 in common stock By Investing.com - Investing.com Nigeria
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells 558 Shares of Stock - MarketBeat
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock: Insider Peter Greenleaf Sells 797 Shares - MarketBeat
Pelthos Therapeutics director Peter Greenleaf sells $16,872 in stock By Investing.com - Investing.com Nigeria
Pelthos Therapeutics director sells $11,560 in common stock - Investing.com
Pelthos Therapeutics director Peter Greenleaf sells $16,872 in stock - Investing.com
Pelthos Therapeutics director Matthew Pauls sells $16,506 in shares - Investing.com
Form 4 Pelthos Therapeutics Inc For: 6 October By Investing.com - Investing.com India
Form 4 Pelthos Therapeutics Inc For: 6 October By Investing.com - Investing.com UK
Under a trading plan, Pelthos Therapeutics (PTHS) director sells 797 shares at $21.17. - Stock Titan
For estimated vesting taxes, a Pelthos Therapeutics (PTHS) director sold 786 shares at $21. - Stock Titan
Pelthos expands ZELSUVMI coverage to 127 million lives - Investing.com
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - The Manila Times
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - GlobeNewswire
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - GlobeNewswire
PTHS PE Ratio & Valuation, Is PTHS Overvalued - Intellectia AI
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com Australia
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Pelthos Therapeutics elects directors and approves new equity plan at annual meeting - Investing.com
Pelthos Shareholders Approve 2026 Equity Plan With 500,000-Share Reserve - Minichart
Form 8K Pelthos Therapeutics Inc For: 1 October By Investing.com - Investing.com UK
Stockholders elect eight directors as Pelthos Therapeutics (PTHS) adopts its 2026 stock incentive plan. - Stock Titan
Pelthos Therapeutics Inc (PTHS-A) Stock Price and News - The Globe and Mail
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings: Deep EPS Miss Sends Shares LowerRevenue Warning Signal - careplusvn.com
Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings: Deep EPS Miss Sends Shares LowerQuarterly Earnings - dars.gov.et
Pelthos Therapeutics Inc. SEC Filing (Aug 18, 2026) - Stock Titan
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewswire
Pelthos Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings call transcript: Pelthos Therapeutics posts Q2 2026 revenue growth, but EPS miss weighs - Investing.com
Pelthos Therapeutics Inc. 2026: Revenue $15.6M, Net income ($23.42M), EPS ($6.62) — 10-Q Summary - TradingView
Earnings To Watch: Pelthos Therapeutics Inc (PTHS) Reports Q2 2026 Result - Yahoo Finance
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026 - GlobeNewswire
Pelthos Therapeutics (PTHS) Surges 9.18% to $28.66: Key Levels to WatchIsland Reversal - careplusvn.com
Pelthos Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives 9.18% Stock JumpNegative Surprise Momentum - careplusvn.com
PTHS Q1 2026 Earnings: Smaller-than-Expected Loss Drives Modest Stock GainWeak Earnings Momentum - careplusvn.com
Pelthos Therapeutics Added to Russell 3000E™ Growth - GlobeNewswire
PTHS Forecast — Price Target — Prediction for 2027 - TradingView
Pelthos Therapeutics stock rises on director share purchase - Investing.com
Why is Pelthos Therapeutics stock rallying today? - Investing.com
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - Yahoo Finance
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pelthos Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Pelthos Therapeutics Announces First Quarter 2026 Financial Results - GlobeNewswire
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain - Yahoo Finance
Pelthos Therapeutics Inc. Stock (PTHS) Financials Data
There is no financial data for Pelthos Therapeutics Inc. (PTHS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Pelthos Therapeutics Inc. Stock (PTHS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pauls Matthew | Director |
Oct 02 '26 |
Sale |
21.00 |
786 |
16,506 |
13,578 |
| Friedberg Ezra M | Director |
Oct 02 '26 |
Sale |
20.72 |
558 |
11,560 |
80,484 |
| Pauls Matthew | Director |
Jul 02 '26 |
Sale |
26.16 |
786 |
20,561 |
14,364 |
| Greenleaf Peter | Director |
Jul 02 '26 |
Sale |
26.13 |
797 |
20,827 |
23,884 |
| Friedberg Ezra M | Director |
Jul 02 '26 |
Sale |
26.09 |
558 |
14,556 |
81,042 |
| Friedberg Ezra M | Director |
Jun 15 '26 |
Sale |
27.29 |
283 |
7,724 |
81,600 |
| Davis Todd C | Director |
Jun 11 '26 |
Buy |
27.82 |
35,948 |
999,983 |
75,834 |
| Francis Knuettel II | Officer |
May 22 '26 |
Proposed Sale |
27.11 |
1,720 |
46,629 |
0 |
| Francis Knuettel II | CFO, Treas & Secty |
May 22 '26 |
Sale |
26.84 |
1,500 |
40,265 |
11,316 |
| Greenleaf Peter | Director |
Apr 02 '26 |
Sale |
20.92 |
797 |
16,670 |
24,681 |
3.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):